2018 Volume 92 Issue 1 Pages 50-53
Objective : We aimed to examine gastrointestinal symptoms, the eradication rate (ER) after first-line therapy, and the degree of atrophy in patients with Helicobacter pylori–associated gastritis.
Methods and Subjects : Between March 2013 and March 2018, of 70 patients diagnosed with atrophic gastritis, according to the Kimura–Takemoto classification, after upper endoscopy and later with H. pylori-associated gastritis after a urea breath test, 69 underwent successful first- or second-line eradication therapy covered by Japan’s National Health Insurance. The global overall symptom scale was administered before H. pylori eradication, and the severity of symptoms was compared between those with successful first-line and those with failed first-line eradication. The first-line H. pylori eradication regimen consisted of 7-day therapy ［esomeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., and clarithromycin 400 mg b.i.d.］.
Results : The ER of first-line therapy was 74.3% (52/70) . Comparisons of CI (ER : 94.4%, 17/18) , CII (ER : 62.5%, 15/24) , and OI (ER : 46.2%, 6/13) showed that the ER was high in cases where the degree of atrophy was low. Stomach-ache, heartburn, stomach oppression, and nausea were significantly milder in patients with successful first-line eradication than in those with failed first-line eradication (p＜0.05) , but there were no differences in the severity of acid reflux, feeling of gastric distension, belching, and loss of appetite.
Conclusion : For cases where patients were diagnosed as having a mild atrophic gastritis, the ER was high. Before H. pylori eradication, stomach ache, heartburn, stomach oppression, and nausea were milder in patients with successful first-line eradication.
